Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low on Wednesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 10000 shares trading hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The firm has a market cap of C$1.33 million, a price-to-earnings ratio of -1.00 and a beta of -0.02. The company has a fifty day moving average price of C$0.01 and a 200-day moving average price of C$0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Recommended Stories
- Five stocks we like better than Aequus Pharmaceuticals
- Want to Profit on the Downtrend? Downtrends, Explained.
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Why is the Ex-Dividend Date Significant to Investors?
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- What is the Dogs of the Dow Strategy? Overview and Examples
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
